ReviewImmune network2015
Proteomics in Rheumatoid Arthritis Research.
Review in Immune network, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Proteomic Profiling Reveals Novel Molecular Insights into Dysregulated Proteins in Established Cases of Rheumatoid Arthritis.Proteomes · 2025Article
- Plasma proteome analysis of rheumatic patients reveals differences in fingerprints based on cardiovascular history: a pilot study.Proteome science · 2025Article
- TASTY trial: protocol for a study on the triad of nutrition, intestinal microbiota and rheumatoid arthritis.Nutrition journal · 2025Article
- Metabolomic Profiling of Blood Plasma in Females with Hyperplasia and Endometrial Cancer.Metabolites · 2024Article
- Machine learning-based remission prediction in rheumatoid arthritis patients treated with biologic disease-modifying anti-rheumatic drugs: findings from the Kuwait rheumatic disease registry.Frontiers in big data · 2024Article
- The protective effect of traditional Chinese medicine Jinteng Qingbi granules on rats with rheumatoid arthritis.Frontiers in pharmacology · 2024Article
- Article
- Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis.Biomedicines · 2022Review
- Quantitative proteomic analysis comparing grades ICRS1 and ICRS3 in patients with osteoarthritis.Experimental and therapeutic medicine · 2021Article
- Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient-Companion Diagnostics.Diagnostics (Basel, Switzerland) · 2021Review
- Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics.Arthritis research & therapy · 2021Article
- Article
- Serum Peptidomic Profile as a Novel Biomarker for Rheumatoid Arthritis.International journal of rheumatology · 2020Article
- Proteomic analysis of human synovial fluid reveals potential diagnostic biomarkers for ankylosing spondylitis.Clinical proteomics · 2020Article
- Early supplemental α2-macroglobulin attenuates cartilage and bone damage by inhibiting inflammation in collagen II-induced arthritis model.International journal of rheumatic diseases · 2019Article
- New Insights for RANKL as a Proinflammatory Modulator in Modeled Inflammatory Arthritis.Frontiers in immunology · 2019Article
- Genomics, transcriptomics and proteomics to elucidate the pathogenesis of rheumatoid arthritis.Rheumatology international · 2017Review
- Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups.Scientific reports · 2017Article
- Folate Receptor-Targeted Diagnostics and Therapeutics for Inflammatory Diseases.Immune network · 2016Review
- Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression.Molecular and cellular biochemistry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although rheumatoid arthritis (RA) is the most common chronic inflammatory autoimmune disease, diagnosis of RA is currently based on clinical manifestations, and there is no simple, practical assessment tool in the clinical field to assess disease activity and severity. Recently, there has been increasing interest in the discovery of new diagnostic RA biomarkers that can assist in evaluating disease activity, severity, and treatment response. Proteomics, the large-scale study of the proteome, has emerged as a powerful technique for protein identification and characterization. For the past 10 years, proteomic techniques have been applied to different biological samples (synovial tissue/fluid, blood, and urine) from RA patients and experimental animal models. In this review, we summarize the current state of the application of proteomics in RA and its importance in identifying biomarkers and treatment targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.